Skip to main content
Download PDF

Jiedu Fuzheng decoction improves the proliferation, migration, invasion and EMT of non-small cell lung cancer via the Wnt/β-catenin pathway

Cell Division volume 18, Article number: 22 (2023) Cite this article

Abstract

Objectives

This study aimed to investigate the effect of Jiedu Fuzheng decoction (JFD) in non-small cell lung cancer (NSCLC) and its potential therapeutic mechanism.

Results

We prepared JFD-medicated serum from rats and treated NSCLC cells (A549 and NCI-H1650) with 0.5, 1, and 2 mg/mL JFD-medicated serum. CCK-8 and colony formation assays were used to detect cell proliferation. Transwell assays showed that JFD attenuated cell migration and invasion. JFD and SKL2001 (Wnt/β-catenin activator) were simultaneously used to treat NSCLC cells to verify that JFD regulated the biological behavior of NSCLC via Wnt/β-catenin signaling. It was found that 2 mg/mL JFD had the most significant effect on the activity of NSCLC cells. JFD attenuated proliferation and metastasis but increased the proportion of apoptotic cells. At the same time, JFD downregulated N-cadherin, vimentin and β-catenin protein expression in cancer cells. SKL2001 could restore the improvement of JFD on proliferation, metastasis and apoptosis.

Conclusion

This study confirmed that JFD suppressed the occurrence and development of NSCLC by regulating Wnt/β-catenin signaling and provided a novel therapeutic scheme for NSCLC.

Highlights

  1. 1.

    JFD inhibited the activity and proliferation of NSCLC cells.

  2. 2.

    JFD inhibited the migration and invasion of NSCLC cells.

  3. 3.

    Activation of the Wnt/β-catenin pathway partially restored the influence of JFD on the NSCLC cell malignant phenotype.

Background

Lung cancer is recognized as the most common malignant tumor, of which 85% is non-small cell lung cancer (NSCLC) [1, 2]. Although there have been encouraging results in the treatment of NSCLC patients through surgical resection, radiotherapy, chemotherapy, immunotherapy and targeted therapy, the prognosis of NSCLC remains poor [3]. Lung cancer kills more than a million people a year, and a significant amount of time and money need to be invested in therapeutic studies for NSCLC each year [4]. Therefore, it is still relevant to explore a novel treatment scheme for NSCLC.

In Asia, especially in China, Chinese herbs have been used as antitumor drugs in clinical treatment. Traditional Chinese medicine formulations not only play a significant role in ameliorating cancer development but also reduce adverse reactions and complications caused by chemotherapy or radiotherapy [2]. Jiedu Fuzheng decoction (JFD) is a Chinese herb that is mainly composed of 13 drugs, such as Jieducao, Nervilia fordii, Chrysanthemum indicum, Oldenlandia, Astragalus membranaceus and Atractylodes macrocephala [5]. The study of Yang et al. confirmed that JFD treatment could reduce the mortality of patients with hepatocarcinoma and extend their lifespan [6]. Studies of ovarian cancer (OV) have also found that FJD may increase the sensitivity of OV to cisplatin by mediating the phosphoinositide 3-kinase (PI3K)/AKT or NF-κB pathways [7]. These studies suggest that JFD has a potential role in improving cancer. Our previous experiments confirmed that JFD could reduce proliferation, but whether JFD can affect NSCLC metastasis has not been reported.

The abnormal proliferation and metastasis of tumor cells are mostly affected by carcinogenic signaling, such as Notch, Wnt/β-catenin, MAPK and Hippo axi [8]. A variety of cellular biological behavior processes are mediated by Wnt/β-catenin signaling. The disorder of the Wnt/β-catenin cascade causes malignant tumors to occur and develop [9]. At the same time, Wnt/β-catenin signaling is regulated by multiple traditional Chinese medicines. Astragalus polysaccharides can induce apoptosis of gastric cancer cells by mediating the Wnt/β-catenin axis, causing cell cycle arrest [10]. Chinese herbal extracts can prevent the progression of SW403 cells by attenuating the Wnt/β-catenin pathway [11]. It is not clear whether JFD can improve the occurrence and progression of NSCLC via Wnt/β-catenin signaling.

In this research, JFD-containing serum was prepared, and NSCLC cells were treated with JFD to verify the influence of JFD on cancer cell behavior. Furthermore, a Wnt/β-catenin activator was added to verify that JFD regulates the development of NSCLC via the Wnt/β-catenin axis. Our study proposes a new therapeutic strategy for therapeutic schemes of NSCLC.

Results

JFD suppresses the proliferation of NSCLC cells

We evaluated the impact of JFD on proliferation and apoptosis. JFD reduced the viability of cancer cells, and 2 mg/mL JFD treatment for 48 h had the best effect (Fig. 1A). JFD significantly reduced the proliferation of tumor cells (Fig. 1B). Furthermore, JFD remarkably promoted apoptosis (Fig. 1C). In summary, JFD can suppress the proliferation of cancer cells

Fig. 1
figure 1

JFD inhibits the proliferation of NSCLC cells. A CCK-8 was used to detect cell viability. B Colony formation was used to determine cell proliferation. C The level of apoptosis was detected by flow cytometry. n = 3. ***p < 0.001

Full size image

JFD suppresses metastasis of lung cancer cells

Next, we examined the effects of JFD on the metastasis of A549 and NCI-H1650 cells. Similarly, JFD markedly reduced the migration (Fig. 2A) and invasion (Fig. 2B) of cancer cells. Epithelial–mesenchymal transition (EMT) marker protein (N-cadherin, E-cadherin, Vimentin and β-catenin) expression mediated by JFD was further analyzed. JFD significantly upregulated E-cadherin but downregulated N-cadherin, vimentin and β-catenin (Fig. 2C). In conclusion, JFD inhibits the metastasis of lung cancer cells.

Fig. 2
figure 2

JFD represses the migration and invasion of NSCLC cells. A Transwell assays were used to detect cell migration. B Transwell assays were used to detect cell invasion. C The protein expression levels of N-cadherin, E-cadherin, Vimentin and β-catenin were detected by western blot. n = 3. **p < 0.01, ***p < 0.001

Full size image

JFD exerted suppressive roles in the proliferation of NSCLC cells via the Wnt/β-catenin axis

The change in Wnt/β-catenin axis activity is related to the proliferation and metastasis of cancer [12]. The level of β-catenin protein was downregulated after JFD treatment (Fig. 2C). To further explore whether JFD regulates cell proliferation via the Wnt/β-catenin axis, we cotreated NSCLC cells with SKL2001 and JFD. We observed that stimulating the Wnt/β-catenin axis partially restored the influences of JFD on cell viability (Fig. 3A) and proliferation (Fig. 3B). Consistently, JFD-induced apoptosis was reduced by activating Wnt/β-catenin signaling (Fig. 3C). The above results indicate that JFD may reduce the proliferation of NSCLC cells via the Wnt/β-catenin axis.

Fig. 3
figure 3

JFD inhibits the proliferation of NSCLC cells through the Wnt/β-catenin pathway. A Cell viability was determined by CCK-8. B Cell proliferation was determined according to colony formation. C Apoptosis was detected by flow cytometry. n = 3. ***p < 0.001

Full size image

JFD inhibits metastasis of cells via the Wnt/β-catenin axis

Finally, we evaluated the regulatory effect of JFD on the metastasis of NSCLC via the Wnt/β-catenin axis. By using JFD and SKL2001 to treat cancer cells simultaneously, it was found that stimulating the Wnt/β-catenin axis restored the inhibitory effect of JFD on cell migration (Fig. 4A) and invasion (Fig. 4B). Similarly, JFD inhibited the process of EMT, while stimulating the Wnt/β-catenin pathway downregulated E-cadherin and upregulated N-cadherin, vimentin and β-catenin (Fig. 4C). In general, JFD may suppress the metastasis of NSCLC via the Wnt/β-catenin axis.

Fig. 4
figure 4

JFD suppresses the migration and invasion of NSCLC cells through the Wnt/β-catenin pathway. A Cell migration was detected by Transwell assays. B Transwell assays were used to detect cell invasion. C The protein expression levels of N-cadherin, E-cadherin, Vimentin and β-catenin were detected by western blot. n = 3. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

Discussion

At present, the incidence and mortality of primary lung cancer in China still rank first [13]. Although the current treatment of NSCLC patients has yielded encouraging results, the recurrence rate of patients after surgical resection is still high [14]. An increasing number of traditional Chinese medicine prescriptions, which have few adverse reactions and a low cost, are used to treat various diseases, including cancer [15]. Our study confirmed that NSCLC cell proliferation and metastasis could be improved by JFD. Further exploration of its molecular mechanism revealed that JFD suppressed the development of lung cancer by inhibiting the Wnt/β-catenin axis (Fig. 5). Our study contributes a reliable research basis for the treatment of cancer in clinical practice, especially NSCLC.

Fig. 5
figure 5

JFD inhibits the proliferation, migration and invasion of NSCLC cells by suppressing the Wnt/β-catenin pathway (by FigDraw)

Full size image

As an effective adjuvant therapy, traditional Chinese medicine has been applied in the clinical treatment of lung cancer. Traditional Chinese medicine can enhance the effect of chemotherapy and radiotherapy through synergistic effects and reduce the adverse reactions and toxicity to patients [16]. JFD has been shown to improve many types of cancer. JFD can extend the lifetime of mice with liver cancer and reduce the metastasis of cancer [17]. A recent study showed that JFD improves the efficacy of cisplatin therapy in ovarian cancer and activates NF-κB signaling by suppressing the PI3K/AKT/mTOR axis [7]. Our study also reached a similar conclusion. We treated cancer cells with different concentrations of JFD and found that JFD inhibited the activity of cancer cells in a concentration-dependent manner. Further detection also confirmed that JFD could regulate the proliferation, migration, invasion and EMT of cancer cells. The inhibitory effect of traditional Chinese medicine decoction on tumors may be achieved through the synergistic effect of multiple targets and multiple signaling pathways [18]. At present, there are many studies and applications of JFD in the treatment of liver cancer. JFD can reduce the expression of genes and related pathways of TP53, CCND1, p-EGFR, EGF, VEGFA, JUN, IL-6, COX-2, AKT1 and MAPK1 in liver cancer cells [19]. We found that JFD inhibited the activation of the Wnt/β-catenin pathway in NSCLC cells. Our study first verified the therapeutic effect of JFD in NSCLC.

The Wnt/β-catenin signaling pathway affects cell growth, development, evolution, and homeostasis [20]. The transcriptional activity of the oncogene β-catenin is essential for regulating the development of cancer [21]. The Wnt/β-catenin axis is crucial in NSCLC cell lines. The activation of the Wnt/β-catenin axis by promoting the level of β-catenin in cancer cells can promote the development of NSCLC [22]. Upregulation of β-catenin protein level in NSCLC may increase the interaction between β-catenin and E-cadherin and improve the prognosis of NSCLC [23]. In previous reports, the main active substances of JFD, such as Scutellaria baicalensis, Astragalus membranaceus and Taraxacum officinale, were related to stimulating Wnt/β-catenin signaling [24,25,26]. We found increased β-catenin in JFD-treated NSCLC cells. Further treatment of cells treated with JFD by using SKL2001 reversed the improvement of JFD on cancer cell proliferation and metastasis. In addition, we also observed that JFD significantly increased E-cadherin protein and decreased N-cadherin and vimentin protein levels in lung cancer cells. The changes in the protein levels of these markers indicate that JFD can lead to the transformation of mesenchymal cells into epithelial cells. Similarly, SKL2001 can restore JFD’s suppression of EMT transition. Therefore, we speculate that JFD can mediate the development of NSCLC by the Wnt/β-catenin axis. EMT is an important process of cancer metastasis, drug resistance and cancer stem cells [27]. We will continue to explore the influence of JFD on lung cancer drug resistance, radiotherapy and chemotherapy.

In conclusion, our study confirmed that JFD regulated the behavior of NSCLC. At the same time, it was found at the molecular level that JFD affected the development of cancer cells through the Wnt/β-catenin axis. However, our research also has certain limitations, and we have only confirmed our conclusions at the cellular level. The use of animal models to study cancer metastasis can better support our conclusions, and we will next verify our conclusions at the animal level.

Methods

JFD preparation

The main components of the decoction were Jieducao 15 g, Forsythia suspensa 15 g, Nervilia fordii 15 g, Chrysanthemum indicum 15 g, Scutellaria baicalensis 15 g, Chinese violet 10 g, Taraxacum officinale 30 g, Oldenlandia 20 g, Sculellaria barbata 20 g, Raw oyster 30 g, Pericarpium Citri Reticulatae 15 g, Astragalus membranaceus 30 g, and Atractylodes macrocephala 20 g. In the first decoction, medicines were soaked with 1200 mL water for 30 min and decocted for 90 min to obtain approximately 200 mL of the medicinal liquid. In the second decoction, 900 mL water was added, and the decoction was carried out for 90 min to obtain approximately 225 mL of liquid. The first and second decoctions were mixed and concentrated to the desired concentration. The low, medium and high doses of JFD were 0.5 mg, 1.0 mg and 2.0 mg crude drug per 1 mL, respectively. JFD was stored at 4 °C for subsequent experiments.

Preparation of medicated serum

Fifteen healthy SPF SD rats (6–8 weeks, 140–180 g) were purchased from Guangdong Medical Experimental Animal Center (Guangdong, China). The rats were randomized into 5 groups (3 rats/group): the control group, gefitinib group (10 µM), JFD low-dose group (0.5 mg/mL), JFD middle-dose group (1 mg/mL) and JFD high-dose group (2 mg/mL). Control rats were given 9% NaCl every day; the gefitinib group was given gefitinib solution by gavage; and the rats in the JFD groups were given low, medium and high doses of JFD decoction by gavage. Gavage was performed once in the morning and evening, 2 mL each time, for 5 consecutive days. The rats were fasted at night before blood collection, and blood samples were drawn from the abdominal aorta 1 h after the last administration on the next day. After standing for 2 h, the samples were centrifuged for 8 min (3000 rpm). Then, the collected serum was incubated at a constant temperature (56 °C) for 30 min, and the inactivated complement was sterilized. Finally, medicated sera were stored at − 20 °C. All animal experiments were approved by the Ethics Committee of The First Affiliated Hospital of Guangxi University of Chinese Medicine.

Cell culture and treatments

Human NSCLC cell lines (A549 and NCI-H1650) were obtained from the American Type Culture Collection (TCGA, Manassas, Virginia, USA). Cells were cultured in DMEM (Sigma‒Aldrich, Darmstadt, Germany) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Gibco, Grand Island, New York, USA) in a 5% CO2 incubator at 37 °C. The cells were cultured in medium containing drug-containing serum. For β-catenin agonist treatment, NSCLC cells were treated with 30 µM SKL2001 (MedChem Express, Monmouth Junction, NJ, USA) for 24 h.

Cell counting Kit-8 (CCK-8) assay

Cells to be detected were inoculated into 96 wells at 5 × 103 cells/well and incubated for 0, 24, and 48 h. Subsequently, 10 µL of CCK-8 solution (Abcam, Cambridge, MA, USA) was added to each well and incubated at 37 °C for 4 h. Finally, the value at 450 nm was read by a microplate reader (Varioskan LUX, Thermo Scientific, Massachusetts, USA).

Colony formation assay

A549 and NCI-H1650 cells were inoculated into 6-well plates (2 × 103 cells/well). After 14 days, the cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet (Beyotime, Shanghai, China) for 30 min. Colony images were taken with a camera, and aerobic colonies were counted using ImageJ software.

Cell apoptosis assay

The cell suspensions were mixed with 1 Annexin V-fluorescein isothiocyanate (10 µL) and propidium iodide (PI, 5 µL) for 30 min at 25 °C in the dark. The apoptosis ratio was determined by FACSCalibur flow cytometry.

Transwell migration and invasion assays

Cells to be detected (2 × 104 cells) without serum were inoculated in the upper chamber of a Transwell (Corning, New York, USA). Normal culture medium containing serum was placed in the lower chamber. For the detection of cell invasion, Matrigel (Sigma-Aldrich) was used to cover the Transwell insert. After 24 h, the cells that did not migrate to or invade the upper chamber were removed. Transwell lower chamber cells were fixed and stained with methanol and crystal violet. Finally, five fields of view were randomly selected using a microscope for observation and counting.

Western blot

A549 and NCI-H1650 cells were placed on ice and lysed with RIPA buffer for 40 min. Total protein levels were quantified. The protein (20 µg) was transferred to a PVDF membrane after electrophoretic separation and blocked with 5% skim milk for 1 h, followed by overnight incubation of the primary antibody with the membrane at 4 °C. The next day, the sample was incubated with HRP-conjugated antibody at room temperature for 30 min. Finally, enhanced chemiluminescence reagents (KeyGen, Nanjing, China) were used for development and recording. The following primary antibodies were purchased from Abcam: anti-N-cadherin (ab76011, 1:5000), anti-E-cadherin (ab40772, 1:10,000), anti-Vimentin (ab92547, 1:2000), anti-β-catenin (ab32572, 1:5000), and anti-GAPDH (ab9485, 1:2500).

Statistical analysis

All data are expressed as the mean ± standard deviation (SD) of three experiments. Statistical analysis was performed using GraphPad Prism 8.0 software. The comparison among multiple groups was assessed by one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test. P < 0.05 was considered statistically significant.

Availability of data and materials

The datasets used or analyzed during the current study are available from the corresponding author upon reasonable request.

Code availability

Not applicable.

Abbreviations

NSCLC:

Non-small cell lung cancer

OV:

Ovarian cancer

JFD:

Jiedu Fuzheng decoction

EMT:

Epithelial–mesenchymal transition

PI3K:

Phosphoinositide 3-kinase

FBS:

Fetal bovine serum

CCK-8:

Cell counting kit-8

SD:

Standard deviation

References

  1. Yu H, Li SB. Role of LINC00152 in non-small cell lung cancer. J Zhejiang Univ Sci B. 2020;21(3):179–91.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Wang MR, et al. Effect of Wenxia Changfu formula combined with cisplatin reversing non-small cell lung cancer cell adhesion-mediated drug resistance. Front Pharmacol. 2020;11: 500137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Rhodin KE, et al. The immunotherapeutic landscape in non-small cell Lung cancer and its surgical horizons. J Thorac Cardiovasc Surg. 2020;159(4):1616–23.

    Article  PubMed  Google Scholar 

  4. Misra P, Singh S. Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective. Cancer Med. 2019;8(5):1976–95.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Shi H, Tian S, Tian H. Network pharmacology interpretation of Fuzheng-Jiedu decoction against colorectal cancer. Evid Based Complement Alternat Med. 2021;2021: 4652492.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yang X, et al. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine. 2021;87: 153575.

    Article  CAS  PubMed  Google Scholar 

  7. Yang H, et al. Fuzheng Jiedu decoction induces apoptosis and enhances cisplatin efficacy in ovarian cancer cells in vitro and in vivo through inhibiting the PI3K/AKT/mTOR/NF-kappaB signaling pathway. Biomed Res Int. 2022. https://doi.org/10.1155/2022/5739909.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Park JH, Pyun WY, Park HW. Cancer Metabolism: phenotype, signaling and therapeutic targets. Cells. 2020;9(10):2308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhang Y, Wang X. Targeting the Wnt/beta-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):165.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chen L, et al. Research Progress on the mechanisms of polysaccharides against gastric cancer. Molecules. 2022;27(18):5828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pan J, et al. Extracts of Zuo Jin Wan, a traditional Chinese medicine, phenocopies 5-HTR1D antagonist in attenuating Wnt/beta-catenin signaling in colorectal cancer cells. BMC Complement Altern Med. 2017;17(1):506.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Yu F, et al. Wnt/beta-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6(1):307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chen P, et al. Non-small cell lung cancer in China. Cancer Commun. 2022;42(10):937–70.

    Article  Google Scholar 

  14. Muthusamy B, Patil PD, Pennell NA. Perioperative systemic therapy for resectable non-small cell lung cancer. J Natl Compr Cancer Netw. 2022;20(8):953–61.

    Article  CAS  Google Scholar 

  15. Li JX, et al. Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. Pharmacol Res. 2021;171: 105574.

    Article  CAS  PubMed  Google Scholar 

  16. Su XL, et al. Clinical application and mechanism of traditional Chinese medicine in treatment of Lung cancer. Chin Med J. 2020;133(24):2987–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Yin LR, et al. Expression of phosphatase and tensin homolog deleted on chromosome ten in liver of athymic mice with hepatocellular carcinoma and the effect of Fuzheng Jiedu decoction. World J Gastroenterol. 2008;14(1):108–13.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Min L, et al. Anti-angiogenic therapy for normalization of tumor vasculature: a potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Mol Med Rep. 2016;13(3):2518–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Yan FN, et al. Molecular targets of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma based on network pharmacology analysis. Cancer Cell Int. 2020;20(1):1–18.

    Article  Google Scholar 

  20. Bian J, et al. Transcriptional regulation of Wnt/beta-catenin pathway in colorectal cancer. Cells. 2020;9(9):2125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Novellasdemunt L, Antas P, Li VS. Targeting wnt signaling in colorectal cancer. a review in the theme: cell signaling: proteins, pathways and mechanisms. Am J Physiol Cell Physiol. 2015;309(8):C511-521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Wang R, et al. An SETD1A/Wnt/beta-catenin feedback loop promotes NSCLC development. J Exp Clin Cancer Res. 2021;40(1):318.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2014;106(1): djt356.

    Article  PubMed  Google Scholar 

  24. Song X, et al. Wogonin influences vascular permeability via Wnt/beta-catenin pathway. Mol Carcinog. 2015;54(7):501–12.

    Article  CAS  PubMed  Google Scholar 

  25. Bian Y, et al. Astragalus Membranaceus (Huangqi) and Rhizoma curcumae (Ezhu) decoction suppresses Colorectal cancer via downregulation of Wnt5/beta-Catenin signal. Chin Med. 2022;17(1):11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhu J, et al. Taraxasterol inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in papillary thyroid cancer cells through regulating the Wnt/beta-catenin signaling. Hum Exp Toxicol. 2021;40(12-suppl):S87–95.

    Article  CAS  PubMed  Google Scholar 

  27. Wang KX, et al. FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer (vol 15, pg 732, 2020). Oncogene. 2020;39(42):6619–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the anonymous reviewers who helped to improve the paper.

Funding

This work was supported by Guangxi Qihuang Scholar Cultivation Project, the Project of Basic Scientific Research Capability Improvement of Young and Middle-aged Teachers of Guangxi Universities (2023KY0306), the Key Subject Construction Project of Guangxi Traditional Chinese Medicine (GZXK-P-20-07), the Doctoral Scientific Research Foundation of Guangxi University of Chinese Medicine (2020BS029), the Youth Foundation of Self-funded Scientific Research Subject of Guangxi Health Commission (Z20200260), the Doctoral Scientific Research Foundation of The First Affiliated Hospital of Guangxi University of Chinese Medicine (2020BS006), and the Self-funded Scientific Research Subject of Guangxi Administration of Traditional Chinese Medicine (GXZYA20220073).

Author information

Author notes

  1. Fang Fang and Xiaowei Jin—co-first authors.

Authors and Affiliations

  1. The Second Ward of Oncology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 327, Xianhu Avenue, Qingxiu District, Nanning, 530001, Guangxi Zhuang Autonomous Region, People’s Republic of China

    Fang Fang, Jiaxiao Wang, Changhong Wang & Wei Shi

  2. Department of Traditional Chinese Medicine, Yunnan Cancer Hospital, Kunming, 650018, Yunnan, People’s Republic of China

    Xiaowei Jin

  3. Guangxi University of Chinese Medicine, Nanning, 530001, Guangxi Zhuang Autonomous Region, People’s Republic of China

    Jinming Meng & Jiaqi He

  4. Preventive Treatment of Disease Center, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9, Dongge Road, Qingxiu District, Nanning, 530001, Guangxi Zhuang Autonomous Region, People’s Republic of China

    Sheng Xie

Authors
  1. Fang Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaowei Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinming Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiaqi He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiaxiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Changhong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sheng Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wei Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

guarantor of integrity of the entire study: SX; study concepts: WS, JW; study design: FF; definition of intellectual content: FF; literature research: XJ; experimental studies: FF, XJ, JM, JH; data acquisition: JM; data analysis: JH; statistical analysis: JM, CW; manuscript preparation: FF; manuscript editing: FF; manuscript review: FF.

Corresponding authors

Correspondence to Sheng Xie or Wei Shi.

Ethics declarations

Ethics approval and consent to participate

All animal experiments were approved by the Ethics Committee of The First Affiliated Hospital of Guangxi University of Chinese Medicine. This research was performed in accordance with the Declaration of Helsinki.

Consent for publication

Not Applicable. This article does not contain any studies with human participants performed by any of the authors.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fang, F., Jin, X., Meng, J. et al. Jiedu Fuzheng decoction improves the proliferation, migration, invasion and EMT of non-small cell lung cancer via the Wnt/β-catenin pathway. Cell Div 18, 22 (2023). https://doi.org/10.1186/s13008-023-00105-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13008-023-00105-7

Keywords

Cell Division

ISSN: 1747-1028

Contact us